NRx Pharmaceuticals Reschedules Q2 2025 Financial Results Release to August 19, 2025
ByAinvest
Wednesday, Aug 13, 2025 6:11 pm ET1min read
NRXP--
The rescheduling is due to the need for additional time to compile certain information and recent developments into the Form 10-Q filing. Investors can access the results via a press release on the company's website and join the conference call through a webcast or by dialing +1-800-717-1738 (domestically) or +1-646-307-1865 (internationally) [2].
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The company's pipeline includes NRX-100 (preservative-free intravenous ketamine) and NRX-101 (oral D-cycloserine/lurasidone), with NRX-100 and NRX-101 receiving Fast Track and Breakthrough Therapy Designations, respectively [1].
References:
[1] https://www.biospace.com/press-releases/nrx-pharmaceuticals-inc-nasdaq-nrxp-to-report-second-quarter-2025-financial-results-on-august-14-2025
[2] https://www.stocktitan.net/news/NRXP/n-rx-pharmaceuticals-inc-nasdaq-nrxp-reschedules-second-quarter-2025-rspkrmpuj7cv.html
NRx Pharmaceuticals reschedules its Q2 2025 financial results release to August 19, 2025, with a conference call on August 20, 2025. The company requires additional time to compile information into the Form 10-Q, including recent developments. The conference call will be available on the company's website, and participants can dial in domestically or internationally to join.
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) has announced a delay in the release of its second quarter 2025 financial results. The company has rescheduled the release to August 19, 2025, after the market close, with a subsequent conference call scheduled for August 20, 2025, at 8:00 AM ET [2].The rescheduling is due to the need for additional time to compile certain information and recent developments into the Form 10-Q filing. Investors can access the results via a press release on the company's website and join the conference call through a webcast or by dialing +1-800-717-1738 (domestically) or +1-646-307-1865 (internationally) [2].
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The company's pipeline includes NRX-100 (preservative-free intravenous ketamine) and NRX-101 (oral D-cycloserine/lurasidone), with NRX-100 and NRX-101 receiving Fast Track and Breakthrough Therapy Designations, respectively [1].
References:
[1] https://www.biospace.com/press-releases/nrx-pharmaceuticals-inc-nasdaq-nrxp-to-report-second-quarter-2025-financial-results-on-august-14-2025
[2] https://www.stocktitan.net/news/NRXP/n-rx-pharmaceuticals-inc-nasdaq-nrxp-reschedules-second-quarter-2025-rspkrmpuj7cv.html
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet